adalimumab (preferred products) — Highmark
Ulcerative Colitis (UC)
Initial criteria
- age ≥ 5 years
- diagnosis of moderate or severe UC
- prescribed by or in consultation with a gastroenterologist
Reauthorization criteria
- member has demonstrated disease stability or a beneficial response to therapy